
Atea Pharmaceuticals (AVIR) P/E Ratio
P/E Ratio as of Jun 13, 2025: -1.92
Average-1.84
Median-1.84
Minimum-1.96
Maximum-1.66
-1.92
Past Month-0.35 (22.29%)
The P/E ratio for Atea Pharmaceuticals (AVIR) is -1.92 as of Jun 13, 2025. This represents a increase of 20.00% compared to its 12-month average P/E ratio of -1.6. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Atea Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Atea Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Atea Pharmaceuticals to industry peers.
Atea Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Atea Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Atea Pharmaceuticals to industry peers.
Atea Pharmaceuticals (AVIR) P/E Ratio Insights
See Atea Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Atea Pharmaceuticals (AVIR)
Order type
Buy in
Order amount
Est. shares
0 shares
Atea Pharmaceuticals (AVIR) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $3.10 | -1.88 |
May 1, 2025 | $2.99 | -1.50 |
Apr 1, 2025 | $2.85 | -1.43 |
Mar 3, 2025 | $2.90 | -1.40 |
Feb 3, 2025 | $2.92 | -1.41 |
Jan 2, 2025 | $3.42 | -1.65 |
Atea Pharmaceuticals (AVIR) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -1.92 | +18.52% |
2024 | -1.62 | -16.49% |
2023 | -1.94 | -114.75% |
2022 | 13.15 | +101.07% |
2021 | 6.54 | -102.07% |
2020 | -316.52 | — |
FAQs About Atea Pharmaceuticals (AVIR) P/E ratio
The latest P/E ratio of Atea Pharmaceuticals (AVIR) is -1.92, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Atea Pharmaceuticals’s last 12-month average P/E ratio is -1.6, compared to its current P/E ratio of -1.92. This reflects a increase of 20.00%.
Atea Pharmaceuticals’s current P/E ratio of -1.92 is higher than its last 12-month average P/E of -1.6. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Atea Pharmaceuticals’s average P/E ratio over the last 3 years is 4.73. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Atea Pharmaceuticals’s average P/E ratio over the last 5 years is -10.38. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.